Aktienanalyse zu BioCryst Pharmaceuticals, Inc. (BCRX)BCRXBioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

BioCryst Pharmaceuticals Inc (BCRX) is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $7.65, which is below the average analyst price target of $11 to $13, indicating potential upside. However, the RSI is at 30.196, suggesting that the stock is oversold, but it also reflects weak momentum. The company reported a significant net income loss of -721,812,000 USD in Q1 2026, raising concerns about its financial health. The main risk is the competitive pressure from Pharvaris, which could reduce Orladeyo's long-term revenue to $400 million to $450 million, impacting overall performance. Given these factors, it may be prudent to hold rather than buy at this time.